May. 14 at 5:41 PM
$COYA $GANX Things can change in a split second. Nobody cared about Coya a day ago at 3.90 and today here we are at
$5.20. Those lamenting having sold at the low only have themselves to blame, allowing emotions to get the best of them.
Both these little and fairly under followed companies are likely to materially impact two awful diseases with no standard of care, ALS and Parkinson's. The ultimate data will likely tell the tale favorably, based on what early trials have already shown. It is amazing how few take the time to actually really look at what is alteady out there and how significant derisking has already occured. Not infallible, but a huge hedge.
I continue to believe both ultimately have new names on the door. DRL for Coya, one of many for Gain.
Patent cliff approaching, pipelines empty, neurological diseases are a highly unmet sweetspot and opportunity.
